Missing pieces in the Parkinson's disease puzzle

Staging of brain pathology related to sporadic Parkinson’s disease

Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240

α-Synuclein Locus Triplication Causes Parkinson's Disease

Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383

Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005

Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease

Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405

Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease

Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366

The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135

Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy

Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×

Parkinson's disease

Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845

The substantia nigra of the human brain

Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751

Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722

A systematic review of prevalence studies of dementia in Parkinson's disease

Aarsland, D., Zaccai, J., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,689

Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors

Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G. W., Cook, E. G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.02.013 · Cited by 1,549

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324

A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307

Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model

Björklund, L. M., Sánchez-Pernaute, R., Chung, S., Andersson, T., Chen, I. Y. C., McNaught, K. S. P., Brownell, A.-L., Jenkins, B. G., Wahlestedt, C., Kim, K.-S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022438099 · Cited by 1,170

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial

Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067

Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases

Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,002

TRANSPLANTATION OF EMBRYONIC DOPAMINE NEURONS FOR SEVERE PARKINSON'S DISEASE

Reed, R., Reene, P. A. E. G., Reeze, R. O. E. B., Ei, W., Ouchel, W. I. D. U. M., Ao, R. I. K., Infield, W., Ulver, S. H. C., Rojanowski, J. O. Q. T., Idelberg, D. A. E., et al. (2001) · Cited by 1,001

‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901

Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease

Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J. G., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321702 · Cited by 860

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829

Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates

Lee, H.-J., Patel, S., & Lee, S.-J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0692-05.2005 · Cited by 797

Prion-like mechanisms in neurodegenerative diseases

Frost, B., & Diamond, M. I. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2786 · Cited by 776

Genetics of Parkinson disease: paradigm shifts and future prospects

Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 707

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease

Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696

Untitled work

(2004) · doi:10.1002/ana.10846 · Cited by 614

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

Harding, A. J., Broe, G. A., & Halliday, G. M. (2002) · Brain · doi:10.1093/brain/awf033 · Cited by 609

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587

The parkinson's complex: Parkinsonism is just the tip of the iceberg

Langston, J. W. (2006) · Annals of Neurology · doi:10.1002/ana.20834 · Cited by 583

The substantia nigra of the human brain

Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578

Hypocretin (orexin) cell loss in Parkinson's disease

Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial

(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561

Cognitive status correlates with neuropathologic stage in Parkinson disease

Braak, H., Rüb, U., Jansen Steur, E. N. H., Del Tredici, K., & de Vos, R. A. I. (2005) · Neurology · doi:10.1212/01.wnl.0000158422.41380.82 · Cited by 560

The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease

Pan, T., Kondo, S., Le, W., & Jankovic, J. (2008) · Brain · doi:10.1093/brain/awm318 · Cited by 546

Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons

Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534

Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease

Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Züchner, S., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 465

A clinico-pathological study of subtypes in Parkinson's disease

Selikhova, M., Williams, D. R., Kempster, P. A., Holton, J. L., Revesz, T., & Lees, A. J. (2009) · Brain · doi:10.1093/brain/awp234 · Cited by 461

Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years

Mendez, I., Viñuela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H., Tierney, T., Holness, R., Dagher, A., Trojanowski, J. Q., et al. (2008) · Nature Medicine · doi:10.1038/nm1752 · Cited by 443

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

Smith, W. W., Pei, Z., Jiang, H., Moore, D. J., Liang, Y., West, A. B., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508052102 · Cited by 424

α-Synuclein and neuronal cell death

Cookson, M. R. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-9 · Cited by 418

The progression of pathology in longitudinally followed patients with Parkinson’s disease

Halliday, G., Hely, M., Reid, W., & Morris, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0344-8 · Cited by 414

Changes in network activity with the progression of Parkinson's disease

Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm086 · Cited by 395

Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways

Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Heiss, W. D. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 384

A critical evaluation of the Braak staging scheme for Parkinson's disease

Burke, R. E., Dauer, W. T., & Vonsattel, J. P. G. (2008) · Annals of Neurology · doi:10.1002/ana.21541 · Cited by 377

Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation

Lutz, A. K., Exner, N., Fett, M. E., Schlehe, J. S., Kloos, K., Lämmermann, K., Brunner, B., Kurz-Drexler, A., Vogel, F., Reichert, A. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.035774 · Cited by 373

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370

A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease

Gibb, W. R. G., & Lees, A. J. (1988) · Neurology · doi:10.1212/wnl.38.9.1402 · Cited by 369

Motor Score of the Unified Parkinson Disease Rating Scale as a Good Predictor of Lewy Body–Associated Neuronal Loss in the Substantia Nigra

Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354

Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study

Aarsland, D., Perry, R., Brown, A., Larsen, J. P., & Ballard, C. (2005) · Annals of Neurology · doi:10.1002/ana.20635 · Cited by 348

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345

Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells

Redmond, D. E., Bjugstad, K. B., Teng, Y. D., Ourednik, V., Ourednik, J., Wakeman, D. R., Parsons, X. H., Gonzalez, R., Blanchard, B. C., Kim, S. U., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704091104 · Cited by 344

Genomic investigation of α‐synuclein multiplication and parkinsonism

Ross, O. A., Braithwaite, A. T., Skipper, L. M., Kachergus, J., Hulihan, M. M., Middleton, F. A., Nishioka, K., Fuchs, J., Gasser, T., Maraganore, D. M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21380 · Cited by 342

Progress toward the clinical application of patient-specific pluripotent stem cells

Kiskinis, E., & Eggan, K. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40553 · Cited by 339

[Epidemiology of Parkinson disease].

Domínguez Carmona, M. (1989) · PubMed · Cited by 330

Research in motion: the enigma of Parkinson's disease pathology spread

Brundin, P., Li, J.-Y., Holton, J. L., Lindvall, O., & Revesz, T. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2477 · Cited by 328

Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease

Kordower, J. H., Freeman, T. B., Chen, E., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Snow, B., & Warren Olanow, C. (1998) · Movement Disorders · doi:10.1002/mds.870130303 · Cited by 298

Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study

O'Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira‐Moriyama, L., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.21813 · Cited by 290 · cited 1×

Transplanted dopaminergic neurons develop PD pathologic changes: A second case report

Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W., & Freeman, T. B. (2008) · Movement Disorders · doi:10.1002/mds.22369 · Cited by 287

Is Parkinson's disease a prion disorder?

Olanow, C. W., & Prusiner, S. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906759106 · Cited by 268

Neurobiology and treatment of Parkinson's disease

Schapira, A. H. V. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.005 · Cited by 264

Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice

Kitada, T., Tong, Y., Gautier, C. A., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06350.x · Cited by 261

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., Lee, C. S., McKenzie, J., McCormick, S., Samii, A., Troiano, A., et al. (2009) · Brain · doi:10.1093/brain/awp209 · Cited by 259

Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258

Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions

Goetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., et al. (2008) · Movement Disorders · doi:10.1002/mds.21894 · Cited by 253

Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252

Calcium homeostasis, selective vulnerability and Parkinson's disease

Chan, C. S., Gertler, T. S., & Surmeier, D. J. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.01.006 · Cited by 237

Parkin-induced mitophagy in the pathogenesis of Parkinson disease

Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2009) · Autophagy · doi:10.4161/auto.5.5.8505 · Cited by 231

Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease

Perier, C., Bové, J., Wu, D.-C., Dehay, B., Choi, D.-K., Jackson-Lewis, V., Rathke-Hartlieb, S., Bouillet, P., Strasser, A., Schulz, J. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609874104 · Cited by 229

The genetics of Parkinson's syndromes: a critical review

Hardy, J., Lewis, P., Revesz, T., Lees, A., & Paisan-Ruiz, C. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.03.008 · Cited by 209

Cognitive decline correlates with neuropathological stage in Parkinson's disease

Braak, H., Rüb, U., & Del Tredici, K. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.011 · Cited by 209

Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease

Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.72 · Cited by 209

Prognostic factors for the progression of Parkinson's disease: A systematic review

Post, B., Merkus, M. P., de Haan, R. J., Speelman, J. D., & CARPA Study Group (2007) · Movement Disorders · doi:10.1002/mds.21537 · Cited by 206

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

Storch, A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.nct60005 · Cited by 205

Clinical and quantitative pathologic correlates of dementia with Lewy bodies

Gómez-Tortosa, E., Newell, K., Irizarry, M. C., Albert, M., Growdon, J. H., & Hyman, B. T. (1999) · Neurology · doi:10.1212/wnl.53.6.1284 · Cited by 204

A Dopaminergic Axon Lattice in the Striatum and Its Relationship with Cortical and Thalamic Terminals

Moss, J., & Bolam, J. P. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2780-08.2008 · Cited by 200

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study

Kempster, P. A., Williams, D. R., Selikhova, M. V., Holton, J. L., Révész, T., & Lees, A. J. (2007) · Brain · doi:10.1093/brain/awm142 · Cited by 194

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy

Ramírez-Valle, F., Braunstein, S., Zavadil, J., Formenti, S. C., & Schneider, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710215 · Cited by 191

Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients

Rinne, J. O., Ma, S. Y., Lee, M. S., Collan, Y. U., & Röyttä, M. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.01.006 · Cited by 186

Recreational physical activity and risk of Parkinson's disease

Thacker, E. L., Chen, H., Patel, A. V., McCullough, M. L., Calle, E. E., Thun, M. J., Schwarzschild, M. A., & Ascherio, A. (2008) · Movement Disorders · doi:10.1002/mds.21772 · Cited by 185

Why have we failed to achieve neuroprotection in Parkinson's disease?

Olanow, C. W., Kieburtz, K., & Schapira, A. H. V. (2009) · Annals of Neurology · doi:10.1002/ana.21461 · Cited by 183

Rate of clinical progression in Parkinson's disease. A prospective study

Schrag, A., Dodel, R., Spottke, A., Bornschein, B., Siebert, U., & Quinn, N. P. (2007) · Movement Disorders · doi:10.1002/mds.21429 · Cited by 171

The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it?

Hawkes, C. H. (2008) · Movement Disorders · doi:10.1002/mds.22242 · Cited by 157

In vivo silencing of alpha-synuclein using naked siRNA

Lewis, J. M., Melrose, H. L., Bumcrot, D. A., Hope, A. D., Zehr, C., Lincoln, S., Braithwaite, A. T., He, Z., Ogholikhan, S., Hinkle, K. M., et al. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-19 · Cited by 151

Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

Sato, K.-I., Hatano, T., Yamashiro, K., Kagohashi, M., Nishioka, K., Izawa, N., Mochizuki, H., Hattori, N., Mori, H., & Mizuno, Y. (2006) · Movement Disorders · doi:10.1002/mds.20993 · Cited by 149

What causes cell death in Parkinson's disease?

Gupta, A., Dawson, V. L., & Dawson, T. M. (2009) · Annals of Neurology · doi:10.1002/ana.21573 · Cited by 148

Diet, Urate, and Parkinson's Disease Risk in Men

Gao, X., Chen, H., Choi, H. K., Curhan, G. C., Schwarzschild, M. A., & Ascherio, A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm385 · Cited by 146

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K., Cunningham, J. J., Printz, M. A., Kordower, J. H., & Bartus, R. T. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.003 · Cited by 145

Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease

Schiesling, C., Kieper, N., Seidel, K., & Krüger, R. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00952.x · Cited by 144

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

Powers, K. M., Kay, D. M., Factor, S. A., Zabetian, C. P., Higgins, D. S., Samii, A., Nutt, J. G., Griffith, A., Leis, B. C., Roberts, J. W., et al. (2007) · Movement Disorders · doi:10.1002/mds.21782 · Cited by 144

Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cells Survive and Integrate into 6-OHDA-Lesioned Rats

Cai, J., Yang, M., Poremsky, E., Kidd, S. K., Schneider, J. S., & Iacovitti, L. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0319 · Cited by 141

Selective loss of pyramidal neurons in the pre‐supplementary motor cortex in Parkinson's disease

Macdonald, V., & Halliday, G. M. (2002) · Movement Disorders · doi:10.1002/mds.10258 · Cited by 136

Epidemiology of Parkinson's disease

Kasten, M., Chade, A., & Tanner, C. M. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83006-5 · Cited by 135

Mitochondrial alterations in Parkinson’s disease: new clues

Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 133

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I

Litvan, I., Halliday, G. M., Hallett, M., Goetz, C. G., Rocca, W. A., Duyckaerts, C. J., Ben‐Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3180415e42 · Cited by 122

Are Parkinson disease patients protected from some but not all cancers?

Inzelberg, R., & Jankovic, J. J. (2007) · Neurology · doi:10.1212/01.wnl.0000277638.63767.b8 · Cited by 121

Genetic determinants of hair color and parkinson's disease risk

Gao, X., Simon, K. C., Han, J., Schwarzschild, M. A., & Ascherio, A. (2009) · Annals of Neurology · doi:10.1002/ana.21535 · Cited by 116

Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons

González‐Hernández, T., Barroso‐Chinea, P., Cruz‐Muros, I., Pérez-Delgado, M. D. M., & Rodríguez, M. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20323 · Cited by 102

Dementia in Parkinson's disease

Aarsland, D., Beyer, M. K., & Kurz, M. W. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283168df0 · Cited by 99

Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control

Brooks, J. A., Ding, J., Simón‐Sánchez, J., Paisán‐Ruiz, C., Singleton, A., & Scholz, S. W. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063917 · Cited by 94

Transcriptional regulation of mesencephalic dopaminergic neurons: The full circle of life and death

Alavian, K. N., Scholz, C., & Simon, H. H. (2007) · Movement Disorders · doi:10.1002/mds.21640 · Cited by 92

Striatal subregional 6‐[18F]fluoro‐ L ‐dopa uptake in early Parkinson's disease: A two‐year follow‐up study

Brück, A., Aalto, S., Nurmi, E., Vahlberg, T. J., Bergman, J., & Rinne, J. O. (2006) · Movement Disorders · doi:10.1002/mds.20855 · Cited by 91

Iron Accumulation in the Substantia Nigra of Patients With Alzheimer Disease and Parkinsonism

Brar, S., Henderson, D. L., Schenck, J. F., & Zimmerman, E. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.586 · Cited by 88

Dopaminergic transplantation for parkinson's disease: Current status and future prospects

Olanow, C. W., Kordower, J. H., Lang, A. E., & Obeso, J. A. (2009) · Annals of Neurology · doi:10.1002/ana.21778 · Cited by 81

Neuroprotection trials in Parkinson's disease: Systematic review

Hart, R. G., Pearce, L. A., Ravina, B. M., Yaltho, T. C., & Marler, J. R. (2008) · Movement Disorders · doi:10.1002/mds.22432 · Cited by 79

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism

DePaolo, J., Göker-Alpan, Ö., Samaddar, T., Lopez, G. J., & Sidransky, E. (2009) · Movement Disorders · doi:10.1002/mds.22538 · Cited by 79

Oxidative Status of DJ-1-dependent Activation of Dopamine Synthesis through Interaction of Tyrosine Hydroxylase and 4-Dihydroxy-l-phenylalanine (l-DOPA) Decarboxylase with DJ-1

Ishikawa, S., Taira, T., Niki, T., Takahashi-Niki, K., Maita, C., Maita, H., Ariga, H., & Iguchi‐Ariga, S. M. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019950 · Cited by 77

Molecular basis of Parkinson's disease

Yang, Y. X., Wood, N. W., & Latchman, D. S. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32831c50df · Cited by 76

Inhibition of brain mitochondrial respiration by dopamine: involvement of H2O2 and hydroxyl radicals but not glutathione–protein–mixed disulfides

Gluck, M., Ehrhart, J., Jayatilleke, E., & Zeevalk, G. D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00938.x · Cited by 61

Protection Against Parkinson’s Disease Progression: Clinical Experience

LeWitt, P. A., & Taylor, D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.007 · Cited by 61

Dysfunctional mitochondria uphold calpain activation: Contribution to Parkinson's disease pathology

Esteves, A. R., Arduíno, D. M., Swerdlow, R. H., Oliveira, C. R., & Cardoso, S. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.011 · Cited by 55

Parkinson's disease and aging: Same or different process?

Hawkes, C. H. (2007) · Movement Disorders · doi:10.1002/mds.21766 · Cited by 49

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II

Litvan, I., Chesselet, M., Gasser, T., Monte, D. A. D., Parker, D., Hagg, T., Hardy, J., Jenner, P. G., Myers, R. H., Price, D. D., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318053716a · Cited by 45

Neural substrates of cognitive skill learning in Parkinson’s disease

Beauchamp, M. H., Dagher, A., Panisset, M., & Doyon, J. (2008) · Brain and Cognition · doi:10.1016/j.bandc.2008.03.008 · Cited by 44

The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability.

Wr, G., Fearnley, J., & Aj, L. (1990) · PubMed · Cited by 43

Clinical trials for neuroprotection in Parkinson??s disease: overcoming angst and futility?

Hung, A. Y., & Schwarzschild, M. A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32826388d6 · Cited by 42

Neurofilament-Immunoreactive Neurons in Alzheimer's Disease and Dementia with Lewy Bodies

Shepherd, C. E., McCann, H., Thiel, E., & Halliday, G. M. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0469 · Cited by 34

Towards gene therapy for Parkinson's disease

Palfi, S. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70066-8 · Cited by 22

2.4 The Relationship between Dopaminergic Axons and Glutamatergic Synapses in the Striatum: Structural Considerations

Moss, J., & Bolam, J. P. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195373035.003.0005 · Cited by 15

Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells

Naoi, M., Yi, H. L., Maruyama, W., Inaba, K., Shamoto‐Nagai, M., Akao, Y., Gerlach, M., & Riederer, P. F. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.08.082 · Cited by 12

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897

Oxidative stress and Parkinson’s disease

Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878

Neuroinflammation in Parkinson's disease

Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657

Parkin Mediates Proteasome-dependent Protein Degradation and Rupture of the Outer Mitochondrial Membrane

Yoshii, S. R., Kishi, C., Ishihara, N., & Mizushima, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209338 · Cited by 612